A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase I Trial to assess the feasibility of Romidepsin combined with Brentuximab
Vedotin for patients requiring Systemic Therapy for Cutaneous T-cell Lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Fox Chase Cancer Center
Collaborators:
Celgene Corporation Seagen Inc. Seattle Genetics, Inc.